$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000145368718000080 Filed on November 08, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$903.0K	$0.00	$27.00K
YoY Change	5211.76%	-100.0%	-97.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.150M	$4.060M	$4.380M
YoY Change	-9.17%	-7.31%	75.2%
% of Gross Profit
Research & Development	$10.26M	$11.89M	$9.504M
YoY Change	-24.67%	25.05%	57.85%
% of Gross Profit
Depreciation & Amortization	$190.0K	$200.0K	$200.0K
YoY Change	5.56%	0.0%	100.0%
% of Gross Profit
Operating Expenses	$15.40M	$15.94M	$13.88M
YoY Change	-20.17%	14.84%	63.0%
Operating Profit		-$15.94M	-$13.85M
YoY Change		15.06%	85.51%
Interest Expense	-$150.0K	$384.0K	$268.0K
YoY Change	15.38%	43.28%	-13.83%
% of Operating Profit
Other Income/Expense, Net	$0.00	$3.000K	-$16.00K
YoY Change	-100.0%	-118.75%	-500.0%
Pretax Income	-$14.65M	-$16.00M	-$14.68M
YoY Change	-25.03%	8.99%	89.91%
Income Tax
% Of Pretax Income
Net Earnings	-$14.65M	-$16.00M	-$14.68M
YoY Change	-25.04%	9.03%	89.91%
Net Earnings / Revenue	-1622.48%		-54355.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$652.6K	-$714.3K	-$664.9K
COMMON SHARES
Basic Shares Outstanding	22.43M shares	22.40M shares	22.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.40M	$50.50M	$104.4M
YoY Change	-61.28%	-51.63%	31.65%
Cash & Equivalents	$37.40M	$50.49M	$72.15M
Short-Term Investments	$0.00	$0.00	$32.20M
Other Short-Term Assets	$80.00K	$5.100M	$3.000M
YoY Change	-96.19%	70.0%	-16.67%
Inventory
Prepaid Expenses
Receivables	$0.00		$0.00
Other Receivables			$0.00
Total Short-Term Assets	$42.08M	$55.57M	$107.4M
YoY Change	-57.36%	-48.24%	28.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.127M	$2.109M	$2.055M
YoY Change	1.72%	2.63%	-0.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$300.0K	$2.600M	$0.00
YoY Change
Total Long-Term Assets	$2.406M	$4.755M	$2.371M
YoY Change	-0.58%	100.55%	-0.46%
TOTAL ASSETS
Total Short-Term Assets	$42.08M	$55.57M	$107.4M
Total Long-Term Assets	$2.406M	$4.755M	$2.371M
Total Assets	$44.48M	$60.32M	$109.7M
YoY Change	-56.0%	-45.02%	27.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.100M	$1.252M	$1.519M
YoY Change	-31.51%	-17.58%	46.06%
Accrued Expenses	$11.70M	$10.22M	$6.547M
YoY Change	36.36%	56.07%	168.98%
Deferred Revenue	$959.0K	$1.863M
YoY Change	21.86%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$21.40M	$21.30M	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$35.14M	$34.63M	$11.32M
YoY Change	220.28%	205.88%	47.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$21.00M
YoY Change	-100.0%	-100.0%	130.77%
Other Long-Term Liabilities	$938.0K	$1.800M	$1.250M
YoY Change	-21.9%	44.0%
Total Long-Term Liabilities	$938.0K	$1.800M	$1.250M
YoY Change	-21.9%	44.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.14M	$34.63M	$11.32M
Total Long-Term Liabilities	$938.0K	$1.800M	$1.250M
Total Liabilities	$49.90M	$50.32M	$44.65M
YoY Change	1.25%	12.71%	119.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$280.4M	-$263.2M	-$197.4M
YoY Change	29.28%	33.37%	43.54%
Common Stock	$3.000K	$3.000K	$2.000K
YoY Change	0.0%	50.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.418M	$7.402M	$65.08M
YoY Change
Total Liabilities & Shareholders Equity	$44.48M	$60.32M	$109.7M
YoY Change	-56.0%	-45.02%	27.91%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$14.65M	-$16.00M	-$14.68M
YoY Change	-25.04%	9.03%	89.91%
Depreciation, Depletion And Amortization	$190.0K	$200.0K	$200.0K
YoY Change	5.56%	0.0%	100.0%
Cash From Operating Activities	-$12.75M	-$16.03M	-$15.44M
YoY Change	0.63%	3.82%	182.27%
INVESTING ACTIVITIES
Capital Expenditures	-$360.0K	-$60.00K	-$120.0K
YoY Change	140.0%	-50.0%	-57.14%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$6.070M	-$2.240M
YoY Change	-100.0%	-370.98%	-88.77%
Cash From Investing Activities	-$380.0K	$6.020M	-$2.380M
YoY Change	-106.22%	-352.94%	-88.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	80.00K	260.0K	7.340M
YoY Change	-98.41%	-96.46%	211.02%
NET CHANGE
Cash From Operating Activities	-12.75M	-16.03M	-15.44M
Cash From Investing Activities	-380.0K	6.020M	-2.380M
Cash From Financing Activities	80.00K	260.0K	7.340M
Net Change In Cash	-13.05M	-9.750M	-10.48M
YoY Change	752.94%	-6.97%	-55.06%
FREE CASH FLOW
Cash From Operating Activities	-$12.75M	-$16.03M	-$15.44M
Capital Expenditures	-$360.0K	-$60.00K	-$120.0K
Free Cash Flow	-$12.39M	-$15.97M	-$15.32M
YoY Change	-1.04%	4.24%	195.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22434212	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	SELECTA BIOSCIENCES INC
	dei	Entity Small Business EntitySmallBusiness	false
CY2017Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	859000	USD
CY2018Q3	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	516000	USD
CY2017Q4	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	1020000	USD
CY2018Q3	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	326000	USD
CY2017Q4	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	175000	USD
CY2018Q3	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	175000	USD
CY2017Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	268000	USD
CY2018Q3	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	828000	USD
CY2017Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	72000	USD
CY2018Q3	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	105000	USD
CY2017Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	3578000	USD
CY2018Q3	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	5714000	USD
CY2017Q4	selb	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent	70698000	USD
CY2018Q3	selb	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent	50485000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3404601	shares
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-673000	USD
CY2018Q1	selb	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent	70698000	USD
CY2017Q4	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	14876000	USD
CY2018Q3	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	15687000	USD
	selb	Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts	903000	USD
	selb	Contractwith Customer Liability Deferred Revenue Revenue Recognized ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized	92000	USD
	selb	Contractwith Customer Liability Increase From Cash Receipts ContractwithCustomerLiabilityIncreaseFromCashReceipts	903000	USD
CY2017Q4	selb	Contractwith Customer Liability Other ContractwithCustomerLiabilityOther	2231000	USD
CY2018Q3	selb	Contractwith Customer Liability Other ContractwithCustomerLiabilityOther	2126000	USD
CY2018Q3	selb	Contractwith Customer Liability Other Current ContractwithCustomerLiabilityOtherCurrent	300000	USD
	selb	Contractwith Customer Liability Other Increase From Cash Receipts ContractwithCustomerLiabilityOtherIncreaseFromCashReceipts	0	USD
CY2018Q3	selb	Contractwith Customer Liability Other Noncurrent ContractwithCustomerLiabilityOtherNoncurrent	1800000	USD
	selb	Contractwith Customer Liability Other Revenue Recognized ContractwithCustomerLiabilityOtherRevenueRecognized	105000	USD
	selb	Debt Instrument Event Of Default Minimum Amount In Excess Of Indebtedness Trigger DebtInstrumentEventOfDefaultMinimumAmountInExcessOfIndebtednessTrigger	300000	USD
	selb	Debt Instrument Event Of Default Minimum Assets Trigger DebtInstrumentEventOfDefaultMinimumAssetsTrigger	300000	USD
CY2017Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	200000	USD
CY2018Q3	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	200000	USD
	selb	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P4Y
	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	29000	USD
	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	0	USD
CY2016Q4	selb	License And Option Agreement Number Of Additional Targets For Which Other Party May Exercise Options For Additional Licenses LicenseAndOptionAgreementNumberOfAdditionalTargetsForWhichOtherPartyMayExerciseOptionsForAdditionalLicenses	4	target
CY2018Q1	selb	Number Of Collaboration Agreements Under Analysis To Quantify Impact Of Adoption NumberOfCollaborationAgreementsUnderAnalysisToQuantifyImpactOfAdoption	3	agreement
	selb	Reimbursement Invoice ReimbursementInvoice	100000	USD
	selb	Tax Cutsand Jobs Act Changein Tax Rate Increase Decrease In Deferred Tax Asset TaxCutsandJobsActChangeinTaxRateIncreaseDecreaseInDeferredTaxAsset	-23400000	USD
	selb	Tax Cutsand Jobs Act Valuation Allowance Deferred Tax Asset Increase Decrease Amount TaxCutsandJobsActValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount	23400000	USD
CY2018Q3	selb	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1252000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-200000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	101000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8580000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10218000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8580000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4158000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4403000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4420000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4517000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4420000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	273128000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	277721000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	273128000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1314000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2872000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1485000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3924000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2595972	shares
CY2017Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	5100	sqft
CY2017Q4	us-gaap	Assets Assets	101100000	USD
CY2018Q3	us-gaap	Assets Assets	60323000	USD
CY2018Q1	us-gaap	Assets Assets	103698000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	98680000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	55568000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	98911000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	25956000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	25956000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	25940000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	25940000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	310000	USD
CY2018Q3	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	2600000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72151000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50485000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50500000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59048000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72543000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71027000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50764000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13495000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20263000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3868662	shares
CY2018Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6069900	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22343254	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22396183	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22343254	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22396183	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14672000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45668000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16042000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50782000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17107000	USD
CY2018Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17813000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	787000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1863000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	787000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	15919000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	13824000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	14089000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	197000	USD
CY2017Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2018Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0725
CY2017Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	151000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	67000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	151000	USD
CY2017Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2018Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	567000	USD
	us-gaap	Depreciation Depreciation	600000	USD
CY2018Q3	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	789000	USD
	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.31
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.27
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	80000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-113000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1902000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1873000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-30000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-113000	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	26000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	97000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-16000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	85000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-673000	USD
CY2018Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4377000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13155000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4056000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13092000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-369000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-215000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3768000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1766000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-66000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	810000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-317000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2399000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	49286000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	50323000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	47456000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101100000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60323000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2816000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	268000	USD
	us-gaap	Interest Expense InterestExpense	847000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	384000	USD
	us-gaap	Interest Expense InterestExpense	1099000	USD
	us-gaap	Interest Paid Net InterestPaidNet	660000	USD
	us-gaap	Interest Paid Net InterestPaidNet	833000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	89000	USD
CY2018Q3	us-gaap	Interest Payable Current InterestPayableCurrent	97000	USD
CY2017Q3	us-gaap	Investment Income Net InvestmentIncomeNet	165000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	379000	USD
CY2018Q3	us-gaap	Investment Income Net InvestmentIncomeNet	295000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	829000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103698000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10973000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	34632000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10973000	USD
CY2017Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	USD
CY2018Q3	us-gaap	Loans Payable Current LoansPayableCurrent	21299000	USD
CY2017Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	21042000	USD
CY2018Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	USD
CY2018Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	21042000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	31000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	16000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60985000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	617000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8205000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25646000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39365000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46413000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-14676000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45777000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-16001000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1400000	USD
CY2018Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1500000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	617000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1482000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	362000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-50685000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	13881000	USD
	us-gaap	Operating Expenses OperatingExpenses	44697000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	15941000	USD
	us-gaap	Operating Expenses OperatingExpenses	50523000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13854000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44507000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15941000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50523000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2219000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	375000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	584000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	79000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-42000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-113000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-97000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	30000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
CY2018Q3	us-gaap	Other Liabilities OtherLiabilities	2100000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1201000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1800000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1201000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	249000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	354000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	584000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	516000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	48736000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	15598000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2109000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2091000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2017Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	0	USD
CY2018Q3	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	53000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12934000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	105000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	620000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	421000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9504000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31542000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11885000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37431000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	76000	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	316000	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	279000	USD
CY2017Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	329000	USD
CY2018Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2646000	USD
CY2018Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2696000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	180000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	196000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6249000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6512000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2091000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216897000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216900000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263154000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263200000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212469000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	190000	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2042000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5083000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2273000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	47120000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	20999000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	41115000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	41655000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	25940000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	8600000	USD
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.089
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	22426493	shares
CY2018Q3	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	25940000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	51814000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	10000000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	56242000	USD
CY2018Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2018Q3	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22082207	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19803551	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22403954	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22368574	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk and Off‑Balance Sheet Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company maintained approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in Russian bank accounts, of which </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> was held in U.S. dollars.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not have any off-balance sheet arrangements as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, accounting for stock-based compensation and estimating accrued research and development expenses. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>

Files In Submission

Name	View Source	Status
0001453687-18-000080-index-headers.html	Edgar Link	pending
0001453687-18-000080-index.html	Edgar Link	pending
0001453687-18-000080.txt	Edgar Link	pending
0001453687-18-000080-xbrl.zip	Edgar Link	pending
exhibit311_9302018.htm	Edgar Link	pending
exhibit312_9302018.htm	Edgar Link	pending
exhibit321_9302018.htm	Edgar Link	pending
exhibit322_9302018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20180930.xml	Edgar Link	completed
selb-20180930.xsd	Edgar Link	pending
selb-20180930_cal.xml	Edgar Link	unprocessable
selb-20180930_def.xml	Edgar Link	unprocessable
selb-20180930_lab.xml	Edgar Link	unprocessable
selb-20180930_pre.xml	Edgar Link	unprocessable
selectabiosciences10-q9302.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2018 Q4 Form 10-Q Financial Statement

#000145368718000080 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2018 Q4 Form 10-Q Financial Statement

#000145368718000080 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac